DrugPatentWatch - Predict Generic Entry, Patent Risk, and Revenue Shifts - Before Your Competitors (original) (raw)
DrugPatentWatch
Updated Daily — 134 Countries
Authoritative biopharmaceutical intelligence — patents, pipelines, litigation, pricing, and global market opportunities — at your fingertips.
As featured in CNN New England Journal of Medicine Nature Reuters Bloomberg FiercePharma
20+
Years of Intelligence
⚖️
Patent Litigation Intelligence
Access full complaints and court documents. Study failed patent challenges to sharpen your litigation strategy and anticipate early generic entry.
→ Litigation Tracker
🔬
Generic Entry Opportunities
Identify drugs with expiring or expired patents. Inform portfolio decisions, conduct due diligence, and track investigational compounds at every stage.
→ Patent Watch
🌐
Global Drug Patents
Evaluate branded and generic market opportunities across 134 countries. Discover markets where competitors have weak or absent patent protection.
→ Global Database
📊
Market Entry Strategy
Assess market potential through historic sales figures. Evaluate buyer power and align distribution methods with reimbursement segmentation data.
→ Sales Analytics
🤖
AI Research Assistant
Get precise answers from our Deep Research Engine — pulling together information from disparate sources with full citations for accuracy and reliability.
→ AI Engine
⚡
Automated Reports & Dashboards
Take the load off your team. Automate monitoring processes, configure custom alerts, and receive intelligence exactly when it matters.
→ Automation Suite
Why Teams Switch
Good instincts are nice.
Great data are better.
People switch to DrugPatentWatch because they're tired of the high cost and low quality of their analysts. You shouldn't have to wait for a report to understand your market.
Every drug is perpetually updatd from primary sources. The latest information is always available — no delays, no filters, no spin.
See why others have switched →
Patent Expiry Opportunities — 2025–2030
Keytruda (pembrolizumab) 2028 High Value
Humira (adalimumab) Expired Generic
Eliquis (apixaban) 2026 Watch
Ozempic (semaglutide) 2032 Monitored
01
They're wrong more than you think.
Analysts aren't oracles. They're people working with the same public data you could access yourself — just a few weeks later, after three rounds of internal review, dressed up in a 60-page PDF with a lot of confident language.
The data doesn't get better in the meantime. A patent expiry date is a patent expiry date. The FDA docket says what it says. You're not paying for insight. You're paying for someone else's reading of the same primary sources — with their biases baked in.
"Analysts add interpretation. Not always accuracy."
02
By the time it lands, it's old.
Drug markets move fast. A competitor files an ANDA. A court issues an injunction. A biosimilar gets the nod. These things happen on a Tuesday.
Your quarterly report arrives on a Thursday — three months later. You've already missed the window. The early-mover advantage went to whoever was watching the primary data in real time. Not waiting for someone to write it up nicely.
"Markets don't wait for your next briefing."
03
And you never see the raw data.
Here's the part nobody talks about. You get the conclusion. You don't get the spreadsheet.
You can't check their working. You can't run your own cut. You can't take it with you when the contract ends. The data is theirs. The methodology is theirs. If you want to ask a different question than the one they answered, that's a new engagement — new invoice, new wait.
"A black box isn't analysis. It's dependency."
The data analysts use
to make their calls?
It's right here.
DrugPatentWatch pulls directly from primary sources — the USPTO, FDA Orange Book, ANDA filings, litigation records, patent registers across 134 countries. Every source an analyst would use. Updated daily. No middleman.
You form your own view. You run your own queries. You export everything and it's yours — permanently. When the contract ends, the data doesn't disappear.
📥
Export everything, keep it forever
Download full datasets in clean, structured formats. Your exports belong to you — not to a subscription you might cancel.
🔄
Updated while you sleep
Every drug profile is refreshed from primary sources daily. No editorial lag. No publication cycle. Just the current state of the data.
🔍
Ask your own questions
Don't inherit someone else's analytical frame. Query the raw data however your strategy demands — and change your query tomorrow if you need to.
💸
A fraction of the cost
Boutique pharma intelligence firms charge 20,000–20,000–20,000–100,000+ per engagement. DrugPatentWatch offers affordable monthly subscriptions to scale with your needs.
"
Found the results very comprehensive. The information told me who potential competitors are and what they are planning based on not only their NDAs and patents, but also references to clinical trials.
"
Knowing when drugs are coming off patent and who to contract with has enabled us to stay ahead of the curve and align ourselves with the proper vendors.
"
An excellent opportunity for LATAM companies to access information on expired and protected patents from the USA and worldwide in a friendly and easy manner.
Global Reach
Used in over 70 countries by leading pharma organizations
From US generics manufacturers to European biotech firms to LATAM distributors — DrugPatentWatch powers critical decisions across the global pharmaceutical industry.
🇺🇸 USA
🇬🇧 UK
🇩🇪 Germany
🇯🇵 Japan
🇫🇷 France
🇮🇳 India
🇨🇦 Canada
🇦🇺 Australia
🇧🇷 Brazil
🇨🇳 China
🇰🇷 Korea
🇮🇱 Israel
🇸🇬 Singapore
🇨🇭 Switzerland
🇸🇦 Saudi Arabia
+55 more
Get Started
Start working smarter today
Join thousands of pharmaceutical professionals who rely on DrugPatentWatch for authoritative, primary-source intelligence — updated every single day.